Novel antitussive strategies.

Abstract:

:Acute and chronic cough represent one of the most common symptoms of medical importance but effective pharmacotherapy is, to all intents and purposes, absent. Numerous initiatives targeting the recently discovered tussive pathways are in progress. Here, we review the current antitussive armamentarium and provide an update on the novel strategies and compounds in development.

journal_name

Drug Discov Today

journal_title

Drug discovery today

authors

Morjaria JB,Dickinson RS,Morice AH

doi

10.1016/j.drudis.2012.11.004

subject

Has Abstract

pub_date

2013-04-01 00:00:00

pages

380-8

issue

7-8

eissn

1359-6446

issn

1878-5832

pii

S1359-6446(12)00372-8

journal_volume

18

pub_type

杂志文章,评审
  • Enantioselective chromatography in drug discovery.

    abstract::Molecular chirality is a fundamental consideration in drug discovery, one necessary to understand and describe biological targets as well as to design effective pharmaceutical agents. Enantioselective chromatography has played an increasing role not only as an analytical tool for chiral analyses, but also as a prepara...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(05)03407-0

    authors: Zhang Y,Wu DR,Wang-Iverson DB,Tymiak AA

    更新日期:2005-04-15 00:00:00

  • 3D structures and ligand specificities of nuclear xenobiotic receptors CAR, PXR and VDR.

    abstract::The nuclear receptors constitutive androstane receptor (CAR), pregnane X receptor (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters. 3D structures for the ligand-binding domain (LBD) of these receptors are abundantl...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.01.001

    authors: Wu B,Li S,Dong D

    更新日期:2013-06-01 00:00:00

  • Organometallic compounds in oncology: implications of novel organotins as antitumor agents.

    abstract::Since the introduction of cisplatin in cancer therapy, metal complexes and organometallic compounds have been gaining growing importance in oncology. The impressive clinical effectiveness of cisplatin is limited by significant side effects and the emergence of drug resistance. Thus, novel classic and unconventional Pt...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.02.002

    authors: Alama A,Tasso B,Novelli F,Sparatore F

    更新日期:2009-05-01 00:00:00

  • Noncoding RNA and epigenetic gene regulation in renal diseases.

    abstract::Kidneys have a major role in normal physiology and metabolic homeostasis. Loss or impairment of kidney function is a common occurrence in several metabolic disorders, including hypertension and diabetes. Chronic kidney disease (CKD) affect nearly 10% of the population worldwide; ranks 18th in the list of causes of dea...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.04.020

    authors: Kota SK,Kota SB

    更新日期:2017-07-01 00:00:00

  • Modulating TNF-alpha signaling with natural products.

    abstract::Natural products have been, and continue to be, a major source of pharmacologically active substances from which drugs can be developed. Currently, tumor necrosis factor-alpha (TNF-alpha) inhibitors from natural origins are being advanced for the treatment of inflammatory disorders. Elevated TNF-alpha synthesis has be...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2006.06.002

    authors: Paul AT,Gohil VM,Bhutani KK

    更新日期:2006-08-01 00:00:00

  • Histone acetyl transferases as emerging drug targets.

    abstract::Post-translational modifications, such as acetylation or phosphorylation, play a crucial role in the regulation of gene transcription in eukaryotes. Different subtypes of histone acetyl transferases (HATs) catalyze the acetylation of histones on specific lysine residues. A potential role of HATs in the pathology of ca...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.06.008

    authors: Dekker FJ,Haisma HJ

    更新日期:2009-10-01 00:00:00

  • Biosynthesis, degradation and pharmacological importance of the fatty acid amides.

    abstract::The identification of two biologically active fatty acid amides, N-arachidonoylethanolamine (anandamide) and oleamide, has generated a great deal of excitement and stimulated considerable research. However, anandamide and oleamide are merely the best-known and best-understood members of a much larger family of biologi...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2008.02.006

    authors: Farrell EK,Merkler DJ

    更新日期:2008-07-01 00:00:00

  • Current challenges and opportunities in nonclinical safety testing of biologics.

    abstract::Nonclinical safety testing of new biotherapeutic entities represents its own challenges and opportunities in drug development. Hot topics in this field have been discussed recently at the 2nd Annual BioSafe European General Membership Meeting. In this feature article, discussions on the challenges surrounding the use ...

    journal_title:Drug discovery today

    pub_type:

    doi:10.1016/j.drudis.2013.08.003

    authors: Kronenberg S,Baumann A,de Haan L,Hinton HJ,Moggs J,Theil FP,Wakefield I,Singer T

    更新日期:2013-12-01 00:00:00

  • Current status and future prospects of toxicogenomics in drug discovery.

    abstract::In drug discovery and development (DDD), the efficacy, safety and cost of new chemical entities are the main concerns of the pharmaceutical industry. Continuously updated and stricter recommendations imposed by regulatory authorities result in greater challenges being faced by the industry. Reliable high-throughput te...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.11.001

    authors: Khan SR,Baghdasarian A,Fahlman RP,Michail K,Siraki AG

    更新日期:2014-05-01 00:00:00

  • Computational chemistry-driven decision making in lead generation.

    abstract::Novel starting points for drug discovery projects are generally found either by screening large collections of compounds or smaller more-focused libraries. Ideally, hundreds or even thousands of actives are initially found, and these need to be reduced to a handful of promising lead series. In several sequential steps...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(05)03703-7

    authors: Schnecke V,Boström J

    更新日期:2006-01-01 00:00:00

  • Nucleus 'hallowed ground' no more.

    abstract::The proces of piecemeal microautophagy of the nucleus describes the way in which autophagy occurs in the nucleus, a realm of the cell once considered to be off limits for autophagy. ...

    journal_title:Drug discovery today

    pub_type: 新闻

    doi:10.1016/s1359-6446(03)02636-9

    authors: Sutherland S

    更新日期:2003-03-15 00:00:00

  • Biomanufacturing: a high-growth industry for North Carolina.

    abstract::The sustained growth of biotechnology in North Carolina has made the state a worldwide leader in biotechnology. ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/S1359-6446(05)03650-0

    authors: Hartl B

    更新日期:2005-11-15 00:00:00

  • Monitor: molecules and profiles.

    abstract::Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(00)01566-x

    authors: Edwards P

    更新日期:2000-10-01 00:00:00

  • Towards the use of hydrogels in the treatment of limbal stem cell deficiency.

    abstract::Corneal blindness caused by limbal stem cell deficiency (LSCD) is a prevailing disorder worldwide. Clinical outcomes for LSCD therapy using amniotic membrane (AM) are unpredictable. Hydrogels can eliminate limitations of standard therapy for LSCD, because they present all the advantages of AM (i.e. biocompatibility, i...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2012.07.012

    authors: Wright B,Mi S,Connon CJ

    更新日期:2013-01-01 00:00:00

  • Compound high-quality criteria: a new vision to guide the development of drugs, current situation.

    abstract::For several decades, the pharmaceutical industry has suffered due to major issues such as reductions of the number of FDA approved drugs and biologics. Several analyses have been highlighted that the 'druglikeness' is one of the strategies to improve succeed rates of screening such as, for instance, high-throughput sc...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.01.005

    authors: Mignani S,Huber S,Tomás H,Rodrigues J,Majoral JP

    更新日期:2016-04-01 00:00:00

  • Current progress in antivascular tumor therapy.

    abstract::The tumor vasculature transports oxygen, nutrients and drugs for crucial roles in tumor therapy. Antivascular therapy directly targets existing tumor vessels to reduce blood perfusion and then inhibit tumor growth. Vascular disrupting agents and ultrasound-stimulated microbubble destruction use chemical toxicity and p...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.06.001

    authors: Ho YJ,Wang TC,Fan CH,Yeh CK

    更新日期:2017-10-01 00:00:00

  • Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery.

    abstract::The inhaled delivery of nanomedicines has attracted much attention in the treatment of lung diseases or systemic diseases. However, there is a lack of understanding about their fate upon lung delivery. Thus, the objective of this review is to summarize physicochemical properties affecting the fate of nanoparticles aft...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.09.023

    authors: Liu Q,Guan J,Qin L,Zhang X,Mao S

    更新日期:2020-01-01 00:00:00

  • Designing a bio-inspired biomimetic in vitro system for the optimization of ex vivo studies of pancreatic cancer.

    abstract::Pancreatic cancer is one of the most aggressive and lethal human malignancies. Drug therapies and radiotherapy are used for treatment as adjuvants to surgery, but outcomes remain disappointing. Advances in tissue engineering suggest that 3D cultures can reflect the in vivo tumor microenvironment and can guarantee a ph...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.01.012

    authors: Totti S,Vernardis SI,Meira L,Pérez-Mancera PA,Costello E,Greenhalf W,Palmer D,Neoptolemos J,Mantalaris A,Velliou EG

    更新日期:2017-04-01 00:00:00

  • Progress in the discovery and development of glutamate carboxypeptidase II inhibitors.

    abstract::During the past 10 years, substantial progress has been made in the discovery and development of small molecule glutamate carboxypeptidase II (GCP II) inhibitors. These inhibitors have provided the necessary tools to investigate the physiological role of GCP II as well as the potential therapeutic benefits of its inhi...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.07.010

    authors: Tsukamoto T,Wozniak KM,Slusher BS

    更新日期:2007-09-01 00:00:00

  • Sharing lessons learnt across European cardiovascular research consortia.

    abstract::Research consortia in Europe often compete with each other for skills, human and technical resources and, eventually, recognition of the scientific impact of their work. In response to the same EU Horizon2020 call, we received funding for our research project proposals to identify and validate novel drug targets for c...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.01.009

    authors: de Jong L,Bobeldijk-Pastorova I,Erdmann J,Bijker-Schreurs M,Schunkert H,Kuivenhoven JA,van Gool AJ

    更新日期:2020-04-01 00:00:00

  • Molecule-pharmacophore superpositioning and pattern matching in computational drug design.

    abstract::Three-dimensional (3D) pharmacophore modeling is a technique for describing the interaction of a small molecule ligand with a macromolecular target. Since chemical features in a pharmacophore model are well known and highly transparent for medicinal chemists, these models are intuitively understandable and have been i...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.09.007

    authors: Wolber G,Seidel T,Bendix F,Langer T

    更新日期:2008-01-01 00:00:00

  • Interaction of tumor cells with the immune system: implications for dendritic cell therapy and cancer progression.

    abstract::There is a continuous demand for preclinical modeling of the interaction of dendritic cells with the immune system and cancer cells. Recent progress in gene expression profiling with nucleic acid microarrays, in silico modeling and in vivo cell and animal approaches for non-clinical proof of safety and efficacy of the...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2012.07.010

    authors: Imhof M,Karas I,Gomez I,Eger A,Imhof M

    更新日期:2013-01-01 00:00:00

  • Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery.

    abstract::The clinical advancement of HIV-1 attachment inhibitors was hindered initially by poor bioavailability. Attempts to identify improved candidates revealed that solubility and dissolution-rate-limited absorption are barriers to achieving adequate antiviral plasma levels. This was mitigated by forming nanosized drugs or ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2014.03.025

    authors: Timmins P,Brown J,Meanwell NA,Hanna GJ,Zhu L,Kadow JF

    更新日期:2014-09-01 00:00:00

  • How do we measure pathology in PAH (lung and RV) and what does it tell us about the disease.

    abstract::The current understanding of the pathology that underlies pulmonary vascular and right ventricular remodeling in pulmonary hypertension is discussed. Although recent studies underscored the importance of intima and media remodeling and, for the first time, the relevance of perivascular inflammation, much is needed to ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.05.022

    authors: Tuder RM

    更新日期:2014-08-01 00:00:00

  • Adenylyl cyclases as innovative therapeutic goals.

    abstract::Pharmacological modulation of intracellular cyclic AMP (cAMP) signalling could provide new therapeutic and experimental tools. Although drugs interfering with this pathway have traditionally targeted membrane receptors, the effector enzyme adenylyl cyclase (AC), which functions as a signalling catalyst, also presents ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.07.007

    authors: Pavan B,Biondi C,Dalpiaz A

    更新日期:2009-10-01 00:00:00

  • Frontal affinity chromatography with MS detection (FAC-MS) in drug discovery.

    abstract::The emergence of a relatively new technique resulting from a combination of frontal affinity chromatography coupled with MS detection (FAC-MS) has extended the capabilities of MS in drug discovery and development. Its application in a broad range of biological systems, together with its label-free operation, relativel...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(04)03360-4

    authors: Slon-Usakiewicz JJ,Ng W,Dai JR,Pasternak A,Redden PR

    更新日期:2005-03-15 00:00:00

  • Technological advances and proteomic applications in drug discovery and target deconvolution: identification of the pleiotropic effects of statins.

    abstract::Proteomic-based techniques provide a powerful tool for identifying the full spectrum of protein targets of a drug, elucidating its mechanism(s) of action, and identifying biomarkers of its efficacy and safety. Herein, we outline the technological advancements in the field, and illustrate the contribution of proteomics...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.03.001

    authors: Banfi C,Baetta R,Gianazza E,Tremoli E

    更新日期:2017-06-01 00:00:00

  • Minimizing the risk of chemically reactive metabolite formation of new drug candidates: implications for preclinical drug design.

    abstract::Many pharmaceutical companies aim to reduce reactive metabolite formation by chemical modification at early stages of drug discovery. A practice often applied is the detection of stable trapping products of electrophilic intermediates with nucleophilic trapping reagents to guide rational structure-based drug design. T...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2016.11.018

    authors: Brink A,Pähler A,Funk C,Schuler F,Schadt S

    更新日期:2017-05-01 00:00:00

  • A novel approach to identifying antiarrhythmic drug targets.

    abstract::Sudden cardiac death, secondary to ventricular fibrillation (VF), remains the leading cause of death in the USA. Recent experimental and theoretical studies suggest that VF could be caused by spiral wave re-entry. The initiation and subsequent break-up of spiral waves has been linked to electrical alternans, a phenome...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/s1359-6446(02)02567-9

    authors: Gilmour RF Jr

    更新日期:2003-02-15 00:00:00

  • A challenging drug development process in the era of personalized medicine.

    abstract::After years of hesitation a larger number of pharmaceutical and biotech companies are now supporting the idea of a more individualized pharmacotherapy. The companies that are now involved in this research-demanding area will have to face several challenges. The key factor for success will be an in-depth molecular unde...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2011.09.010

    authors: Jørgensen JT

    更新日期:2011-10-01 00:00:00